December 3rd, 格隆汇｜ Roivant will stop developing a drug to treat a rare lung disease because the drug failed to demonstrate therapeutic effects in a mid-stage trial. Kinevant Sciences, a company under the Roivant umbrella, announced on Tuesday that their monthly injectable drug nanomab did not meet its primary and secondary endpoints in a study evaluating about 107 patients with chronic active pulmonary sarcomatoid tumors over a period of approximately 6 months. This disease forms inflammatory cell masses in the lungs and other organs, leading to tissue damage and organ dysfunction. According to the American Lung Association, sarcomatoid tumors affect 0.15 million to 0.2 million people in the usa each year.